April 24, 2018
HALIFAX, April 10, 2018 – kneat.com, inc. (TSX-V: KSI) (“Kneat” or the “Company”) is pleased to announce that it has closed its previously announced brokered private placement for aggregate gross proceeds of $ $6,184,647 (the “Offering”), which was increased from the previously announced amount of $5 million due to investor demand. Through a syndicate of agents led by Echelon Wealth Partners Inc., and including Bloom Burton Securities Inc. and Industrial Alliance Securities Inc. (together, the “Agents”), the Company issued 6,871,830 common shares at an issue price of $0.90 per common share. The Company paid the Agents a cash commission equal to six percent (6%) of the gross proceeds of the Offering and issued warrants entitling the Agents to purchase that number of common shares equal to six percent (6%) of the common shares sold as part of the Offering at an exercise price of $0.90 per common share for a period of 18 months (excluding the 922,221 common shares issued under the President’s List as part of the Offering).
Read the full press release here.
<
>
Canada in Science - November 9, 2018
America's Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub
Canada in Science - September 7, 2018
Q2 2018 Share Price Performance
Canada in Science - August 3, 2018
Canada in Science - July 6, 2018
Greenbrook TMS Announces Closing of Private Placement Totaling USD $20,000,000
Canada in Science - June 7, 2018
CannTrust™ Announces Closing of $100,395,000 Bought Deal
Bloom Burton & Co. Welcomes Michael J. Brown, CFA® as Portfolio Manager and Chief Executive Officer of its Asset Management Affiliate, Bloom Burton Investment Group.
Q1 2018 Share Price Performance
From Motor City to Health Innovation City? Detroit's Unexpected Comeback
Kneat Announces Closing of $6.185 Million Brokered Private Placement
Canada in Science - April 6, 2018
Sunniva Inc. Closes $27.8 Million Bought Deal Public Offering
Immunovaccine Announces Closing of CAD$14,375,000 Bought Deal Offering with Over-Allotment Option Exercised in Full
Canada in Science - March 2, 2018
Big Pharma's Drug War: Innovative vs. Generic and Biosimilar Drugs
Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala
Canada in Science - Feb 2, 2018
Plasma for Profit: The Changing Landscape of Blood Donation
Q4 & Annual 2017 Share Price Performance - Part 3
Q4 & Annual 2017 Share Price Performance - Part 2
ESSA Completes US$26 Million Equity Offering
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer
Q4 Share Price Performance in 2017 - Part 1
BELLUS Health Closes $20M Common Share Financing
Canada in Science - December 1, 2017
Avivagen Announces Closing of Private Placement Totaling $4,000,000
CannTrust™ Announces Closing of $20,000,000 Bought Deal
The Emergence of the HIV/AIDS Epidemic and How it Affected the Human Plasma Industry
Q3 Share Price Performance in 2017 - Part 3
Q3 Share Price Performance in 2017 - Part 2
Q3 Share Price Performance in 2017 - Part 1
Canada in Science - November 3, 2017
Acquisitions in the Life Sciences Start-Up Space: A Principal-Agent Problem in the Making
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin Clinical Trials on ATI-1501